PMID- 37715882
OWN - NLM
STAT- Publisher
LR  - 20230916
IS  - 1559-0305 (Electronic)
IS  - 1073-6085 (Linking)
DP  - 2023 Sep 16
TI  - Reverse Vaccinology and Immunoinformatic Approach for Designing a Bivalent 
      Vaccine Candidate Against Hepatitis A and Hepatitis B Viruses.
LID - 10.1007/s12033-023-00867-z [doi]
AB  - Hepatitis A and B are two crucial viral infections that still dramatically affect 
      public health worldwide. Hepatitis A Virus (HAV) is the main cause of acute 
      hepatitis, whereas Hepatitis B Virus (HBV) leads to the chronic form of the 
      disease, possibly cirrhosis or liver failure. Therefore, vaccination has always 
      been considered the most effective preventive method against pathogens. At this 
      moment, we aimed at the immunoinformatic analysis of HAV-Viral Protein 1 (VP1) as 
      the major capsid protein to come up with the most conserved immunogenic truncated 
      protein to be fused by HBV surface antigen (HBs Ag) to achieve a bivalent vaccine 
      against HAV and HBV using an AAY linker. Various computational approaches were 
      employed to predict highly conserved regions and the most immunogenic B-cell and 
      T-cell epitopes of HAV-VP1 capsid protein in both humans and BALB/c. Moreover, 
      the predicted fusion protein was analyzed regarding primary and secondary 
      structures and also homology validation. Afterward, the three-dimensional 
      structure of vaccine constructs docked with various toll-like receptors (TLR) 2, 
      4 and 7. According to the bioinformatics tools, the region of 99-259 amino acids 
      of VP1 was selected with high immunogenicity and conserved epitopes. T-cell 
      epitope prediction showed that this region contains 32 antigenic peptides for 
      Human leukocyte antigen (HLA) class I and 20 antigenic peptides in terms of HLA 
      class II which are almost fully conserved in the Iranian population. The vaccine 
      design includes 5 linear and 4 conformational B-cell lymphocyte (BCL) epitopes to 
      induce humoral immune responses. The designed VP1-AAY-HBsAg fusion protein has 
      the potency to be constructed and expressed to achieve a bivalent vaccine 
      candidate, especially in the Iranian population. These findings led us to claim 
      that the designed vaccine candidate provides potential pathways for creating an 
      exploratory vaccine against Hepatitis A and Hepatitis B Viruses with high 
      confidence for the identified strains.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Ahmadi, Neda
AU  - Ahmadi N
AD  - Department of Microbiology, Faculty of Biological Sciences, North Tehran Branch, 
      Islamic Azad University, Tehran, Iran.
FAU - Aghasadeghi, Mohammadreza
AU  - Aghasadeghi M
AD  - Department of Hepatitis and AIDS and Blood Borne Diseases, Pasteur Institute of 
      Iran, No: 69, Pasteur Ave, Tehran, 13165, Iran.
AD  - Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran.
FAU - Hamidi-Fard, Mojtaba
AU  - Hamidi-Fard M
AD  - Department of Hepatitis and AIDS and Blood Borne Diseases, Pasteur Institute of 
      Iran, No: 69, Pasteur Ave, Tehran, 13165, Iran.
AD  - Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran.
FAU - Motevalli, Fatemeh
AU  - Motevalli F
AD  - Department of Hepatitis and AIDS and Blood Borne Diseases, Pasteur Institute of 
      Iran, No: 69, Pasteur Ave, Tehran, 13165, Iran.
FAU - Bahramali, Golnaz
AU  - Bahramali G
AUID- ORCID: 0000-0002-1762-4907
AD  - Department of Hepatitis and AIDS and Blood Borne Diseases, Pasteur Institute of 
      Iran, No: 69, Pasteur Ave, Tehran, 13165, Iran. gbahramali@gmail.com.
AD  - Viral Vaccine Research Center, Pasteur Institute of Iran, Tehran, Iran. 
      gbahramali@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20230916
PL  - Switzerland
TA  - Mol Biotechnol
JT  - Molecular biotechnology
JID - 9423533
SB  - IM
OTO - NOTNLM
OT  - HAV-VP1 protein
OT  - Hepatitis A virus
OT  - Hepatitis B virus
OT  - Immunoinformatic
OT  - Recombinant vaccine
EDAT- 2023/09/16 20:42
MHDA- 2023/09/16 20:42
CRDT- 2023/09/16 11:08
PHST- 2023/02/22 00:00 [received]
PHST- 2023/08/21 00:00 [accepted]
PHST- 2023/09/16 20:42 [medline]
PHST- 2023/09/16 20:42 [pubmed]
PHST- 2023/09/16 11:08 [entrez]
AID - 10.1007/s12033-023-00867-z [pii]
AID - 10.1007/s12033-023-00867-z [doi]
PST - aheadofprint
SO  - Mol Biotechnol. 2023 Sep 16. doi: 10.1007/s12033-023-00867-z.